Logo do repositório
 
Publicação

Use of 18F-fluorodeoxyglucose positron emission tomography to standardize clinical trial recruitment in Takayasu’s arteritis

2022Artigo científico Acesso restrito
Ver registo simples
dc.contributor.authorQuinn, Kaitlin A.
dc.contributor.authorAlessi, Hugh D.
dc.contributor.authorPonte, Cristina
dc.contributor.authorRose, Emily
dc.contributor.authorAhlman, Mark A.
dc.contributor.authorRedmond, Christopher
dc.contributor.authorLuo, Yiming
dc.contributor.authorBolek, Ertugrul Cagri
dc.contributor.authorLangford, Carol A.
dc.contributor.authorMerkel, Peter A.
dc.contributor.authorGrayson, Peter C.
dc.date.accessioned2022-10-14T15:00:22Z
dc.date.available2022-10-14T15:00:22Z
dc.date.issued2022
dc.description© Published by Oxford University Press on behalf of the British Society for Rheumatology 2022. This work is written by US Government employees and is in the public domain in the US.pt_PT
dc.description.abstractObjectives: To assess whether data from 18F-fluorodeoxyglucose (FDG) PET should be incorporated into eligibility criteria for clinical trials in Takayasu's arteritis (TAK). Methods: The study was conducted in two parts. Part one was an international online survey among physicians with experience managing TAK to determine, using clinical vignettes, whether FDG-PET data influence decisions about enrolment in trials. Part two used patient data from an observational cohort study in TAK to assess agreement regarding decisions about enrolment into trials, based on clinical assessment with and without incorporation of FDG-PET data. Results: In part one, 68 physicians responded to the survey. Most physicians had used FDG-PET to diagnose TAK (82%) or monitor disease activity (66%). In vignettes representing active clinical disease, FDG-PET findings increased physician confidence in disease assessment and reduced outlier assessments. The greatest variability in decisions regarding enrolment into trials was observed in vignettes representing constitutional symptoms alone and elevated acute-phase reactants. In these cases, FDG-PET findings influenced decisions about enrolment and improved physician confidence. In multivariable models, FDG-PET findings were 1.29 times more strongly associated with enrolment decisions compared with levels of acute-phase reactants. In part two, incorporation of FDG-PET data significantly improved agreement about enrolment decisions between raters [inter-rater reliability (IRR) = 0.68 (95% CI 0.67, 0.69) to IRR = 0.88 (95% CI 0.87, 0.89); P < 0.01]. Conclusions: Incorporation of FDG-PET data into assessment of TAK influences decisions about enrolment of patients into trials, improves physician confidence about clinical assessment and could help reduce variability in study populations. Future trials in TAK should consider incorporating FDG-PET data into eligibility criteria.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationRheumatology (Oxford). 2022 Oct 6;61(10):4047-4055pt_PT
dc.identifier.doi10.1093/rheumatology/keac021pt_PT
dc.identifier.eissn1462-0332
dc.identifier.issn1462-0324
dc.identifier.urihttp://hdl.handle.net/10451/54782
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherOxford University Presspt_PT
dc.relation.publisherversionhttps://academic.oup.com/rheumatologypt_PT
dc.subjectTakayasu’s arteritispt_PT
dc.subjectClinical trialspt_PT
dc.subjectPositron emission tomographypt_PT
dc.titleUse of 18F-fluorodeoxyglucose positron emission tomography to standardize clinical trial recruitment in Takayasu’s arteritispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage4055pt_PT
oaire.citation.issue10pt_PT
oaire.citation.startPage4047pt_PT
oaire.citation.titleRheumatologypt_PT
oaire.citation.volume61pt_PT
person.familyNamePonte
person.givenNameCristina
person.identifier.ciencia-id3713-901B-4493
person.identifier.orcid0000-0002-3989-1192
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication22483f4f-a4d7-48f5-9fae-cc5ae926528a
relation.isAuthorOfPublication.latestForDiscovery22483f4f-a4d7-48f5-9fae-cc5ae926528a

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
18F_fluorodeoxyglucose.pdf
Tamanho:
426.34 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

IMM - Artigos em Revistas Internacionais
FM-CUR-Artigos em Revistas Internacionais